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Abstract
Background The aim of this study was to develop, together
with the Lung Foundation Netherlands and Dutch Kidney
Patients Association, patients and clinicians, a measure to
evaluate patient experiences with the orphan drugs pir-
fenidone (for idiopathic pulmonary fibrosis [IPF]) and
eculizumab (for atypical haemolytic uraemic syndrome
[aHUS]), as well as a generic measure of patient experi-
ences and satisfaction with medications.
Methods Development of the Patient Experiences and
Satisfaction with Medications (PESaM) questionnaire
consisted of four phases: literature review (phase I); focus
groups and individual patient interviews (phase II); item
generation (phase III); and face and content validity testing
(phase IV). Literature review aimed to identify existing
disease-specific and generic patient experience measures to
provide guidance on the domains of medication use rele-
vant to patients, the number of items and type of response
categories, and to generate an initial pool of items. Sub-
sequent focus groups and patient interviews were con-
ducted to gain insight into the perceived effectiveness of
the therapies, the burden of side effects, and how the
medication impacted on a patient’s daily life. Focus groups
and interviews were recorded and transcribed verbatim.
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Coding was carried out by highlighting passages in the text
and assigning each passage a code representing the fol-
lowing predefined categories: (1) perceived effectiveness;
(2) side effects; (3) ease of use; and (4) impact of medi-
cation. Using data from phase I and II, a panel of experts
selected items relevant for inclusion in the questionnaire.
Individual patient interviews with IPF and aHUS patients
(n = 18), using a retrospective verbal probing technique,
were conducted to assess face validity, time needed to fill
out the questionnaire, and content validity.
Results The PESaM questionnaire that was developed
consisted of two disease-specific modules that assessed
patient experiences with pirfenidone for the treatment of
IPF, and eculizumab for the treatment of aHUS, a generic
module, applicable to any medication, and a module to
assess patient expectations. Review of the literature iden-
tified multiple disease- or medication-specific question-
naires and two generic patient satisfaction questionnaires.
Common domains across most questionnaires were effec-
tiveness, side effects, ease of use and overall satisfaction.
Patient interviews revealed the social impact (e.g. unable to
go outside) of side effects such as photosensitivity asso-
ciated with pirfenidone and the risk of infection associated
with eculizumab. Each PESaM module focuses on patients’
perceived effectiveness of the medication, side effects, and
ease of use, and the impact these aspects have on physical
and emotional health and daily life. The generic module
additionally includes items related to satisfaction with the
medication. Individual interviews with patients in phase IV
confirmed, in general, that questions and response options
of the modules were clear and content validity was good.
The mean time to complete the modules ranged from 6 min
for the disease-specific (aHUS) module to 9 min for the
generic module.
Conclusions We developed the PESaM questionnaire to
quantitatively assess patient experiences and satisfaction
with medications. A validation study is currently underway
to examine the psychometric properties of the PESaM
questionnaire.
Key Points for Decision Makers
Data on patient experiences with novel drug
therapies provide insight into how patients feel and
function, and how the treatment impacts their lives.
A measure to quantitatively and systematically
collect patient experiences is currently lacking.
The Patient Experiences and Satisfaction with
Medications (PESaM) questionnaire was developed
together with patients, clinicians and patient
organisations.
The PESaM questionnaire may be employed to
facilitate communication between patients and care
providers, and guide treatment choices or to better
incorporate the patient perspective in the
reimbursement decision-making process.
1 Background
The importance of patient experiences when assessing the
value of novel drug therapies and in optimising care is
increasingly recognised [1–7]. Clinical outcomes and
health-related quality-of-life measures alone may not be
able to include all relevant benefits, harms and character-
istics of a therapy to the patient. Patient experiences can
refer to patients’ reports of structure and process aspects of
care such as accessibility, information, waiting times and
choice of provider [8–11]. These patient experiences are
regularly used as health care quality indicators [12–15].
However, patient experiences can also refer to the way the
patient evaluates health care outcomes, either in general or
related to a specific treatment [11, 16–19]. These ‘subjec-
tive experiences’ incorporate an evaluation or value
judgement regarding aspects and outcomes of health care
provision and treatments. For example, if a specific drug
therapy is administered through weekly intravenous injec-
tions in hospital, the term ‘patient experience’ may refer to
the patient’s objective report of this fact (i.e. the actual
administration mode and frequency) [20]. On the other
hand, a subjective patient experience refers to how the
patient is affected by this fact, e.g. in terms of inconve-
nience and perceived impact on daily life. Patients’ sub-
jective experiences are unlikely to be fully represented in
traditional clinical outcomes. Furthermore, health-related
quality-of-life instruments usually miss out on process
aspects of treatment considered important to patients, yet
they can directly influence outcomes such as satisfaction,
adherence to medication, and, ultimately, treatment effec-
tiveness [16, 21–24].
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Evaluation of subjective patient experiences with med-
ications can be useful in several decision-making contexts.
In a clinical setting, it can provide a more complete
understanding of the impact of a therapy on the patient’s
life and aid treatment choices [2, 7]. Quantitative and
systematic assessment of patient experiences could also
provide scientific evidence for guideline development that
incorporates the patient’s perspective [6, 25]. Alternatively,
assessment of patient experiences may broaden the per-
spective of formal assessments regarding the utility of new
drugs aimed to inform reimbursement decision making
[4, 25]. To date, the patients’ views and experiences with
medications are mostly considered through active patient
participation, i.e. consultation rounds with patients or
patient representatives, patient memberships in commit-
tees, or, indirectly, through personal anecdotes from
patients [25, 26]. Alternatively, the patient perspective can
be considered by systematically measuring patients’
experiences with medications, providing a more scientific
foundation for the incorporation of the patient perspective
in decision making [25]. To our knowledge, a measure to
evaluate such patient experiences is currently lacking.
In 2015, two patient organisations in The Nether-
lands—the Lung Foundation Netherlands and The Dutch
Kidney Patients Association—together with patients,
health scientists, government representatives and physi-
cians, launched a project to develop a measure to better
capture patient experiences with the new drug pirfenidone
(for idiopathic pulmonary fibrosis [IPF]), and eculizumab
(for atypical haemolytic uraemic syndrome [aHUS]).
These orphan drugs had been granted conditional
approval for reimbursement by the Dutch government,
requiring a national registry with physiological outcomes
as well as evaluation of patient-reported outcomes such as
health-related quality-of-life and patient experiences as
input for a re-evaluation after 4 years [27]. In addition,
health care providers expressed a need to obtain more
insight into the patients’ perspectives and experiences
during disease course and treatment, to monitor and
improve care delivery, and promote tailored use. In IPF
and aHUS, there is a paucity of well-validated patient-
reported outcome measures (PROMs) reflecting how
patients feel and function while receiving treatment, and
how treatment impacts their lives [7]. Hence, the aim of
this study was to jointly develop a measure to evaluate
patient experiences with pirfenidone (for IPF) and eculi-
zumab (for aHUS), as well as a generic measure of patient
experiences with medications. In this paper we describe
the development and pretesting of the ‘Patient Experi-
ences and Satisfaction with Medications’ (PESaM)
questionnaire.
2 Conceptual Model and Context
2.1 Conceptual Model
Strasser’s holistic model for patient satisfaction distinguishes
patient experiences, expectations and satisfaction, andwas used
as input for the conceptual framework for the PESaM ques-
tionnaire [18]. The conceptual framework is centred around the
patient’s subjective experience of a stimulus (situation, event or
outcome) related to medication use, for example a side effect
(Fig. 1). The subjective experience is the result of the patient’s
internal process in which he/she identifies, interprets, values
and/or evaluates the stimulus. How the patient experiences the
stimulus depends on his/her individual characteristics, such as
sociodemographics, health status, beliefs, values and expecta-
tions. Satisfaction, in turn, is the attitudinal response to the
patient’s subjective experience. This attitudinal response sub-
sequently predicts a behavioural reaction (e.g. adherence) [18].
Expectations are central to the interpretation of satisfaction; a
patient’s experience may be negative (e.g. ‘the side effects
negatively impact on my ability to work’), but the patient may
nevertheless report high levels of satisfaction with treatment if
this negative experience met prior expectations [28].
Since patient experiences, satisfaction, and expectations
are interrelated, the measure that was developed to evaluate
patient experiences encompasses all three concepts, i.e. the
PESaM questionnaire focuses on patients’ subjective
experiences regarding a medication’s effectiveness (per-
ceived efficacy and impact), side effects (bothersomeness
and impact) and ease of use (inconvenience and impact),
expectations, and (dis)satisfaction.
2.2 Context
The PESaM questionnaire was developed and pretested in
IPF and aHUS patients. IPF is a chronic and progressive lung
disease that is characterised by irreversible loss of lung
function [29]. Prognosis is poor, with an average survival of
3–5 years after diagnosis, and treatment options are limited
[30]. At the start of the project, the antifibrotic agent pir-
fenidone was recommended for treatment. During the course
of the project (in November 2015) a second antifibrotic
agent, nintedanib, became available for IPF patients [31, 32].
Pirfenidone and nintedanib both reduce the rate of disease
progression but are not equally effective in all patients. As a
consequence, potential side effects of these drugs need to be
balanced with the treatment effect [33, 34]. Evaluation of
patient experiences can thus play a significant role when
considering treatment approaches [35, 36]. In The Nether-
lands, it is estimated that between 800 and 1600 people are
diagnosed with IPF each year [37]. Pirfenidone and
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nintedanib are currently conditionally reimbursed in The
Netherlands for patients with IPF with a certain range of
pulmonary function impairment (forced vital capacity
[FVC]B80% predicted or a demonstrated decline in disease,
and an FVC C50% predicted). As a result, while epidemio-
logical data are still limited, clinical experts estimated that
approximately 250 patients across the country were receiv-
ing pirfenidone or nintedanib in 2015. Atypical HUS is an
extremely rare and life-threatening disease characterised by
sudden abnormal breakdown of red blood cells, low platelet
counts, and acute renal failure [38]. Atypical HUS can occur
in children (60%) and adults (40%). People with aHUS are at
constant risk of sudden and progressive damage to and fail-
ure of vital organs, particularly the kidneys. The prognosis
for people with aHUS is poor, with approximately 2–10% of
people with the disease dying in the initial, acute phase. In
50% of aHUS cases, end-stage kidney failure develops,
requiring dialysis [38], and, later on, renal transplantation,
with increased risks of developing aHUS (20–100%) in the
renal transplant [38, 39]. National epidemiological data of
aHUS are limited but it is estimated that only 15–20 people
are diagnosedwith aHUS each year, ofwhom three to five are
children. With the implementation of the new drug eculi-
zumab, outcome perspective improved significantly; how-
ever, the costs of the drug are tremendously high, i.e. up to
€500,000 per patient per year for only the drug itself [40, 41].
3 Methods
The development of the PESaM questionnaire consisted of
four phases: literature review (I); focus groups and indi-
vidual interviews (II); item generation and questionnaire
development (III); and face and content validity test (IV).
3.1 Literature Review
A literature review was conducted to (i) identify whether
there were existing patient experience measures suit-
able for our patient population, and (ii) compile an over-
view of existing measures focused on experiences and
satisfaction with medications. Existing measures were used
to identify domains of medication use relevant to patients,
provide guidance on the number of items and type of
response categories, and to generate an initial series of
items. A search of MEDLINE (from inception to 12
February 2015) was conducted using the following terms in
the title or abstract: ‘measure’ or ‘questionnaire’ or ‘sur-
vey’ or ‘tool’ or ‘instrument’ AND ‘medication’ or ‘drugs’
or ‘pharmacotherapy’ AND ‘experience’ or ‘satisfaction’
or ‘beliefs’ or ‘views’ or ‘preferences’ AND ‘validity’ or
‘validation’ or ‘psychometric properties’ or ‘evaluation’ or
‘assessment’ or ‘reliability’. A paper was included if (i) it
reported on a measure assessing patient experience or
satisfaction with medication; (ii) psychometric properties
were evaluated; and (iii) a copy of the measure (or item
description) was available. Questionnaires that focused on
medication adherence and the broader concept of treatment
burden were excluded. Treatment burden takes into
account everything patients do to take care of their (mul-
tiple) chronic illness, including issues outside the scope of
the PESaM project, such as economic burden, medical
tests, lifestyle changes, and impact of the illness on family
[42].
3.2 Focus Groups and Individual Interviews
Focus groups and individual interviews were held to gain a
deeper understanding and obtain information directly from
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Fig. 1 Conceptual framework
PESaM questionnaire (adapted
from Strasser et al. [18]). Patient
expectations regarding drug
therapy and outcomes (block A)
are evaluated in the expectations
module of the PESaM
questionnaire. The disease-
specific modules assess stimuli
(block B) and subjective
experiences (block C) related to
a specific therapy and patient
group. The generic module
focuses on subjective
experiences (block C) and
satisfaction (block D) with any
drug therapy. PESaM Patient
Experiences and Satisfaction
with Medications
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patients about their experiences with eculizumab and pir-
fenidone. The interviews assisted to refine the content pool
for the PESaM items. An interview guide containing a
number of broad and open-ended questions, exploring three
targeted domains (efficacy, side effects and ease of use),
supported the collection of data (Online Appendices A and
B). The questions were designed to encourage patients to
describe their experiences using their own language. The
following topics were discussed: patients’ perceptions
regarding effectiveness of the medication, experienced side
effects and their bothersomeness, ease of use, advantages
and disadvantages of the medication, impact on everyday
life, and overall satisfaction with the medication. Partici-
pants were probed for final thoughts, including what, if
any, additional themes could be added that might impact
satisfaction or dissatisfaction with the medication.
Focus groups took place between June and September
2015. Two medical specialists, based in two distinct hos-
pitals in The Netherlands, were asked to invite outpatients
with IPF and using pirfenidone to participate in a focus
group. One medical specialist (MW) was part of the project
team and the other (author RM) was approached by the
team based on his expertise with IPF patients and experi-
ence with pirfenidone treatment. MW is based in the
Erasmus Medical Centre, a university hospital in the city of
Rotterdam and expert centre for interstitial lung diseases.
RM is based in the Zuyderland Medical Centre, a periph-
eral hospital in the south of The Netherlands. Due to the
small IPF patient population, convenience sampling was
used aimed at including participants who reflected a range
of the patient population in terms of age, sex and time on
medication. The medical specialist initially informed eli-
gible patients about the focus group and handed out the
patient information sheet. If the patient agreed, contact
details were provided to the researcher (MK or AR), who
would then contact the patient to further explain the study
purpose and procedures, and ask whether the patient was
willing to participate. Written consent was collected before
the start of the focus groups. The focus groups were held in
the hospitals of the participating medical specialists. It was
anticipated that a focus group would last between 1.5 and
2 h (including a short coffee break).
For aHUS patients, individual face-to-face interviews
were conducted (either in hospital or at the patient’s home)
since this disease is extremely rare and patients lived
scattered around the country. One hour was scheduled for
the individual interviews. Interviews were facilitated by
one of two researchers (MK or AR) in the team with
experience in conducting qualitative interviews and with
no prior relationship with the participants. Field notes were
made during the interviews and focus groups. In addition,
all interviews were digitally recorded. Interviews were
transcribed verbatim, with all identifiable information
removed to protect the anonymity of the patients. The data
were subjected to manual qualitative analysis by two data
coders (MK and AR). Coding was carried out by high-
lighting passages in the text and assigning each passage a
code representing the following predefined categories: (1)
perceived effectiveness; (2) side effects; (3) ease of use;
and (4) impact of medication. The categories were based
on the topics from the interview guide. If a category was
identified that did not fit one of the codes, it was assigned
the code ‘other’. The passages in category 4 (impact of the
medication) where then grouped into subcategories, again
predetermined by the interview guide (i.e. physical, emo-
tional, social) or newly emerging (i.e. ‘other’) [43].
3.3 Item Generation and Questionnaire
Development
The PESaM questionnaire was developed by a panel of
experts involved in all steps of the process. The panel was
made up of two experts in health outcomes research, one
health sciences researcher, four medical specialists, two
policy advisors of patient organisations (of aHUS and IPF,
respectively), and one policy advisor of the National Health
Care Institute (ZiNL). The contents and themes derived
from existing satisfaction measures, focus groups and
individual interviews, and discussions with the panel of
experts were used to define domains, potential categories
within the domains, and a first pool of items relevant for
inclusion in the PESaM questionnaire. This initial pool of
items was discussed in a face-to-face meeting with the
panel of experts and an independent board of advisors (four
experts in the field of expensive medications, implemen-
tation of guidelines, health care decision making, and
pharmaceutical care). During this meeting, the initial items,
as well as different types of response options, the appro-
priate recall period, minimum age, and questionnaire
instructions were discussed. Following this meeting a
second, shorter version of the questionnaire was developed.
Any deletion of items or adjustments were based on
majority agreement. After several rounds of drafting,
evaluation and revision among the panel of experts, the
questionnaire was reviewed by a language consultant spe-
cialised in low literacy. She reviewed the readability to
ensure broad applicability among patients. Last adjust-
ments based on her advice led to the final version ready for
the face and content validity test.
3.4 Face and Content Validity Test
Individual patient interviews (n = 18) were conducted to
assess the face validity (comprehensibility of the instruc-
tions, questions and response options), the time needed to
fill out the questionnaire, and the content validity (item
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relevance and missing domains or items). Interviews were
conducted, if possible, with different patients than those
used for the development of the questionnaire. However,
new eligible aHUS patients, willing to participate, could
not be identified between the individual interviews (June to
September 2015) and the face validity tests (January 2016).
Interviews employed a retrospective verbal probing tech-
nique. In this technique, a participant completes a paper
and pencil version of the questionnaire. After completion
of the questionnaire, the interviewer ‘probes’ further into
the basis for the response [44]. Interviewer notes were
complemented with the help of audio recordings.
The study protocol for the development and pretesting
of the measure was reviewed and approved by the Medical
Ethics Committee of Erasmus Medical Centre (MEC-2015-
265). The study is registered in The Netherlands National
Trial Register (code 5860).
4 Results
4.1 Identification of Existing Measures
The literature review led to 1238 references. Review of
titles and abstracts revealed 18 relevant papers describing 2
generic and 14 medication-specific measures that fulfilled
our inclusion criteria. Measures (either disease-specific or
generic) that focused exclusively on subjective experiences
with medications were not identified. An overview of
measures and their domains is presented in Online
Appendix C.
Fourteen disease-specific measures relating to a wide
range of illnesses and conditions were identified that could
serve as examples for our PESaM questionnaire: intraoc-
ular pressure [45, 46], osteoporosis [47], schizophrenia
[48], diabetes [49], migraine [50], asthma [51, 52],
osteoarthritis [53], pain [54, 55], Crohn’s disease [56],
overactive bladder [57] and cancer [58]. Some measures
focused on a specific type of treatment (e.g. drops, inhaled
asthma treatment), while others focused on ‘your medica-
tion’ or ‘your treatment’ more generally. All measures
focused on the concept of satisfaction. Most measures had
multiple items in one or more of the following domains:
effectiveness, side effects, ease of use, impact on everyday
life, quality of life, functional benefit, and overall percep-
tion/global satisfaction. The number of items in the mea-
sures ranged from 1 to 32, with most measures (64%)
having between 15 and 25 items. Most item responses were
recorded on a 5-, 6- or 7-point rating Likert-type scale
(very dissatisfied to very satisfied, disagree to agree, always
to never, etc.).
The ‘Treatment Satisfaction Questionnaire for Medica-
tion’ (TSQM) [59, 60] and the ‘Treatment Satisfaction with
Medicines Questionnaire’ (SATMED-Q) [61] were two
valid multidimensional questionnaires measuring satisfac-
tion with treatment with medicines. The TSQM consists of
14 questions and provides scores on four domains: side
effects, effectiveness, convenience and global satisfaction
[59]. Items were scaled using either a 5- or 7-point scale.
Five-point scales were used for unidimensional continua
(e.g. ‘extremely’ to ‘not at all’), while 7-point scales were
used for bipolar continua (e.g. ‘extremely positive’ to
‘extremely negative’). The SATMED-Q consists of 17
questions and has six domains: treatment effectiveness,
convenience of use, impact on daily living/activities,
medical care, undesirable side effects, and global satis-
faction. Response items were scaled using a 5-point scale
ranging from ‘not at all’ to ‘very much’ [61].
4.2 Focus Groups and Individual Interviews
Two focus groups with six and seven IPF patients using
pirfenidone, respectively, were conducted. As planned, the
focus groups lasted between 1.5 and 2 h. The mean age of
IPF patients was 69 years (range 55–77 years) and most
patients (85%) were male. The mean time on treatment was
15 months (range 2–36).
Four face-to-face individual interviews with aHUS
patients using eculizumab were conducted. Patients were
all female and mean age was 37 years (range 24–46 years).
The mean time since diagnosis of aHUS was 3 years. All
patients were currently using eculizumab and had been
using the medication on and off for the past 6 months to
3 years. Interviews lasted between 45 and 60 min. Ideally,
one or two extra interviews with aHUS patients receiving
eculizumab were conducted, but due to the extreme rarity
of the disease, no other patients were eligible and willing to
participate.
4.2.1 Idiopathic Pulmonary Fibrosis
Table 1 provides an overview of issues related to pir-
fenidone use that were extracted from the focus groups.
Most, but not all, respondents had the feeling that the
medicine stabilised their (decrease in) health and lung
function. Furthermore, these respondents experienced a
decrease in coughing, fatigue, and dyspnoea. As a result,
they felt that the medicine had a positive effect on daily life
and would increase life expectancy.
‘‘I used to cough 24 hours a day, it makes you exhaus-
ted. I am very satisfied because I don’t cough anymore, it
must be the pirfenidone’’ (male, 71 years).
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Respondents expressed they found it difficult to discern
the effects of pirfenidone from the effect of other medi-
cations and treatments they were receiving (e.g. physical
rehabilitation or medications to treat side effects and
comorbidities). Some respondents who had recently started
the medication did not yet feel the medication helped them
and they did experience side effects. Often, together with
their doctors, they decided to (temporarily) reduce the daily
doses of the medication. Side effects that respondents
experienced were coughing, dry mouth, appetite loss,
nausea, diarrhoea, stomach complaints, photosensitivity,
sweating, rash, fatigue, sleepiness and muscular pain. They
felt that side effects negatively impacted their quality of
life. For example, three patients expressed that photosen-
sitivity (i.e. sunburn) was so severe that they could not go
outside on a clear day or felt uncomfortable taking a break
to a sunny destination.
‘‘The only thing I worry about is the sun. Because you
have to use factor 35 or 50 and that’s awful cause I got
family in Portugal but I just don’t want to go on a holiday, I
mean what’s the fun of sitting in the shade and not even
being able to walk down the street without a hat and
gloves’’ (male, 65 years).
Nevertheless, participants with advanced stages of IPF
expressed they feel they ‘have no choice’ due to the
severity of their disease and limited treatment options,
therefore side effects were taken for granted. Regarding
ease of use, respondents mainly complained about the
packaging of the medicines and the frequency of taking the
medicines (two to three times a day). Furthermore, the need
to take the medicines together with food also required strict
planning when going out for (part of) the day.
4.2.2 Atypical Haemolytic Uremic Syndrome
Table 2 provides an overview of issues related to eculi-
zumab use that were extracted from the interviews.
Respondents experienced, as an effect of eculizumab, that
the signs of disease diminished and health improved. They
expressed they felt better, less sick and less tired. Patients
experienced that they had more energy to participate in
society, enjoy social activities, and take care of their
family.
‘‘I don’t have enough energy to work full-time, but I can
care for my young son again and do some voluntary work’’
(female, 37 years).
Side effects that respondents experienced were nausea,
vomiting, bruises, hair loss, joint pain, tremor, pain in the
legs, fatigue, a moody feeling and loss of sight. Fatigue was
most debilitating in the first days after receiving the ther-
apy. Respondents did find it difficult to separate side effects
from actual symptoms of aHUS. Furthermore, patients
worried about possible long-term sequelae and their
increased risk of infection. Because of their fear of infec-
tions, some respondents avoided busy public places and
food they felt would impose a higher risk of infections.
Table 1 Summary of responses extracted from the idiopathic pul-
monary fibrosis focus groups (n = 13)
Category
(domain)
Responses
Effectiveness Stable health
Stable long capacity
Stable disease progression
Longer life expectancy
Reduced coughing
Side effects Coughing
Dry mouth
Loss of appetite
Nausea
Diarrhoea
Photosensitivity (skin burn)
Sweating
Dry skin
Rash
Muscle pain
Tiredness
Low energy levels
Sleepiness
Ease of use Inconvenient packaging
Restricted alcohol use
Need to plan meals
Frequent intake
Impact on
everyday life
Physical
Prevent lung transplantation
Feeling better
Being able to do things
Emotional
More positive outlook
Social
Not able to go on holiday and enjoy the sun (due
to photosensitivity)
Not able to go outside on a sunny day (due to
photosensitivity)
Other
Continuity of life through stable health
Other Exhaustion (symptom of the disease)
Shortness of breath when being active (symptom
of the disease)
Difficult to be active (symptom of the disease)
Limited oxygen leading to headache (symptom of
the disease)
Good service from the pharmacist [home
delivery] (process aspect of care)
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‘‘I avoid airplanes and air-conditioning, I even don’t kiss
(greet) my best friend anymore… . These infections spread
via air, personal contact’’ (female, 46 years).
Regarding ease of use, some respondents were bothered
by the frequency of administration, administration in
hospital, and the intravenous administration. However,
they much preferred receiving eculizumab than the dialysis
they had received or would otherwise need. While side
effects and administration mode were important to
respondents, they were extremely grateful and satisfied
with the therapy as they felt they could not have survived
or participate in everyday life without the medication.
‘‘Without eculizumab I would be on dialysis 3 times a
week, with all associated consequences. I wouldn’t be able
to participate in society, and I am so young’’ (female,
24 years).
4.3 Item Generation and Questionnaire
Development
Existing measures identified in the literature review, dis-
cussion with experts, and the focus groups and individual
interviews with patients resulted in the PESaM question-
naire, which consisted of four modules: two disease-
specific modules for the treatment of IPF (10 items) and
aHUS (12 items), respectively; a generic module (16
items), applicable to any medication; and a patient expec-
tations module (11 items). The modules can be used in
combination or separately. Online Appendix D provides a
summary table of the content of the four modules. All
modules start with a short instruction. Patients are
instructed what drug, and for which disease/diagnosis, the
items in the module refer to. It is emphasized that the items
are about their personal experiences with the drugs, and
thus there are no right or wrong answers, and that they
should tick the response option that best describes their
personal perception or feeling. The recall period for the
items in the disease-specific and generic modules is ‘in the
past 4 weeks’.
In general, all modules follow a similar structure and
focus on patients’ experiences (or expectations in the
expectations module) related to three domains: effective-
ness, side effects, and ease of use of the medication. Items
within these domains relate to the perceived impact of the
medication on aspects of physical health, emotional health,
and everyday life (social and work). A 5-point (Likert-
type) scale with the following anchor levels was chosen as
the response format for most items: ‘not at all’, ‘a little’,
‘reasonable’, ‘a lot’ and ‘very much’. It was advised by the
language consultant to describe the response categories in
greater detail to facilitate comprehension. For example,
when an item asks to what extent a respondent was both-
ered by side effects of the medication, response categories
were ‘not at all bothered’, ‘a little bothered’, etc., rather
than only ‘not at all’ and ‘a little’. We also assumed that
respondents experienced a positive influence of the effec-
tiveness of a medication (if any) and a negative influence of
side effects (if any).
Table 2 Summary of responses extracted from the atypical haemo-
lytic uraemic syndrome interviews (n = 4)
Category Responses
Effectiveness Recovery of the body
Stable health
Staying alive
Prevent recurrence of disease
More energy
Side effects Hair loss
Bruising
Vomiting
Nausea
Tremor
Muscle pain
Pain in the legs
Fatigue
Blurry vision/vision impairment
Lack of energy
Moody
Risk of meningitis
Risk of infections
Ease of use Frequency of hospital visits
Intravenous insertion
Administration not possible at home
Impact on everyday
life
Physical
Better fitness levels
Feeling better/less sick
Return to ‘old’ life before illness
Emotional
Life changing/avoiding death
Unknown long-term harms of treatment
(worry)
Feeling protected against the disease
(reassurance)
Social
Participate in family life
Participation in society
Avoiding busy public spaces
Active social life
Preventing dialysis or kidney transplant
Other
Need for immediate access to antibiotics
Avoiding treatments with increased risk of
infection
Change diet (avoid certain foods)
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The disease-specific modules for aHUS and IPF were
developed in close collaboration with clinicians and with
input from patients through the focus groups and individual
interviews. The modules evaluate patients’ experiences of
the medication regarding specific disease symptoms and
provide a checklist of potentially experienced side effects
(see Online Appendix D). Identified issues (e.g. side
effects) from the focus groups and interviews were gen-
erally operationalised as items in the domains of the dis-
ease-specific modules. For example, the module for aHUS
asks about the influence of eculizumab on energy levels
and the ability to participate in society, fear of infection
(meningitis), and disease recurrence. For each experienced
side effect included in the checklist, such as tremor, fatigue
and muscle pain, respondents are asked to rate how both-
ered they are by that side effect. A category ‘other side
effect’ was available in case a patient experienced a side
effect not present in the checklist. The module for IPF
focuses on its perceived ability to slow down disease
progression (rather than cure), feeling tired and out of
breath, and whether respondents experienced side effects
such as photosensitivity and diarrhoea (see Online
Appendix D). The items in ease of use focus on the
potential inconvenience of mode of administration and
whether patients have skipped medication.
The focus groups and individual interviews revealed that
patients have difficulties distinguishing symptoms of the
disease with side effects, or effects of one medication from
the effects of another, and thus a ‘don’t know’ response
category was available for items, if applicable.
Besides two disease-specific modules, the PESaM
questionnaire includes two generic modules that can be
used for any medication: one that focuses on patient
experiences, and one that focuses on patient expectations.
The generic module for patient experiences focuses on
perceived effectiveness, side effects and ease of use, and
their impact on physical health, emotional health and
everyday life, and also includes an item regarding satis-
faction for each domain, one item about overall (dis)sat-
isfaction with the medication, and a final item to assess the
relative importance of the three domains (Fig. 2). Satis-
faction items are scored on a numeric rating scale ranging
from -5 (not at all satisfied) to ?5 (very satisfied). The
generic modules, in contrast to the disease-specific mod-
ules, do not include any disease- or medication-specific
items, such as specific symptoms that are targeted by the
therapy or specific side effects experienced.
The structure and items of the module focused on
expectations are similar to the items of the generic expe-
riences module; however, questions relate to expectations
rather than experiences (see Appendix D). For example,
where item 1 of the generic module is ‘‘How effective has
the medication been over the past four weeks?’’, the item in
the expectations module is ‘‘How effective do you expect
the medication to be?’’. The expectations module is meant
for administration before the start of a new drug and can
serve as a baseline measurement.
4.4 Face and Content Validity
Thirteen respondents completed the generic and disease-
specific modules, in two rounds of interviews. Four
respondents had aHUS and were currently using eculizu-
mab, five respondents had IPF and were currently using
pirfenidone, and four respondents had IPF and were cur-
rently using nintedanib. The expectations module was
completed by five respondents (all IPF patients; three
commencing treatment with pirfenidone and two com-
mencing treatment with nintedanib) who either started their
medication up to 3 days before or were due to start in the
next few weeks.
The first round of interviews (n = 6) identified some
problems that required adaptation of the modules. Two
respondents overlooked ‘positive influence’ in the first
items of the generic modules and therefore this expression
was emphasized using bold text. Furthermore, the
instruction to skip remaining items in the domain when a
respondent did not experience any side effects (in the
generic experiences module) was often overlooked. This
was also emphasized using bold text. The overall satis-
faction question was shortened as respondents had diffi-
culty comprehending the question because of its length.
Finally, regarding the item about skipping medication
because of side effects or ease of use, respondents missed
an answer category to indicate they skipped the medication
for reasons other than side effects or inconvenience, such
as simply forgetting or having the flu. Hence, the answer
categories were adapted to reflect this potential response.
The second round of interviews (n = 12) tested the
adapted modules. Overall, all items in these versions were
well understood by patients and were reported to be rele-
vant. One respondent felt the questions relating to side
effects and ease of use were irrelevant as the efficacy of the
medication was most important since this resulted in her
still being alive. On the other hand, another respondent felt
that negative aspects (side effects) should receive more
attention. The majority of respondents felt the questions
appropriately covered most relevant aspects of their expe-
riences with, or expectations of, the medications. Missing
items or side effects were not reported by respondents.
Hence, face and content validity were considered good and
no more changes were needed.
On average, the generic module was completed in 9 min
(range 5–17 min), the disease-specific module for IPF was
also completed in 9 min (range 5–16 min), the module for
aHUS was completed in 6 min (range 5–8 min), and the
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expectations module was completed in 6 min (range
5–8 min). The instructions were clear to all respondents
and there were no missing responses.
5 Discussion
The aim of this study was to develop, together with clini-
cians, patients and patient representatives, a measure to
evaluate patient experiences with the orphan drugs pir-
fenidone (for IPF) and eculizumab (for aHUS), as well as a
generic measure of patient experiences and satisfaction
with medications. The PESaM questionnaire, consisting of
four modules, which evaluates patient experiences, satis-
faction and expectations regarding the use of medications,
was developed. Specific attention was given to conceptual
basis, universality, self-administration, number of items,
response options and accessibility of the questionnaire
[62, 63]. The generic modules are applicable to multiple
therapies (medications). The layout, language and uniform
response options promote accessibility for respondents
with low (health) literacy levels. Face validity tests with 18
patients confirmed that questions and response options of
the different PESaM modules were clear and content
validity was good. While the disease-specific module was
originally developed for use in IPF patients using pir-
fenidone, it is also suitable for the new antifibrotic agent
nintedanib. Treatment efficacy and side effects are com-
parable between the two therapies, although the prevalence
and severity of the side effects differ. Diarrhoea is the most
commonly reported side effect of nintedanib [33].
The generic module includes questions on (dis)satis-
faction with each domain, and an overall satisfaction item.
This is in line with Strasser’s suggestion that patient sat-
isfaction is both a multidimensional construct and a sum-
mary construct (a unique summary judgement) since
patients form both types of judgements [18]. However, due
to the addition of satisfaction items for each domain, the
generic module has some overlap with other generic patient
satisfaction measures such as the TSQM and SATMED-Q,
which also focus on (among other domains) effectiveness,
side effects and ease of use of medications [59, 61]. Nev-
ertheless, the generic module distinguishes itself from these
measures by evaluating experiences and satisfaction sepa-
rately; items on satisfaction are distinct from subjective
experiences and their impact on health. Hence, experiences
may be negative (e.g. a respondent reports that the side
effects of the medication negatively impacted on daily
Items Domain
1. Eﬃcacy of medicaon
2. Posive inﬂuence on physical health (e.g. walking, cycling)
3. Posive inﬂuence on feelings and emoons (e.g. fear, joy)
4. Posive inﬂuence on social acvies (e.g. work, family, friends)
5. Sasfacon (or dissasfacon) with eﬀecveness
6. Bothersomeness of sideeﬀects
7. Negave inﬂuence on physical health (e.g. walking, cycling)
8. Negave inﬂuence on feelings and emoons (e.g. fear, joy)
9. Negave inﬂuence on social acvies (e.g. work, family, 
friends)
10. Sasfacon (or dissasfacon) with sideeﬀects
11. Bothersomeness/inconvenience of administraon mode
12. Bothersomeness/inconvenience of me table (frequency)
13. Inconvenient to incorporate in everyday life
14. Sasfacon (or dissasfacon) with ease of use
15. Overall (dis)sasfacon with medicaon
16. Importance of eﬀecveness, sideeﬀects and ease of use
Eﬀecveness
Side eﬀects
Ease of use
Paent
experience
Concept
Overall
sasfacon
Sasfacon
Sasfacon
Sasfacon
Fig. 2 Items of the generic experiences module of the PESaM questionnaire. PESaM Patient Experiences and Satisfaction with Medication
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life), but patients may still be satisfied; a strong relation-
ship between experiences and satisfaction is not a prereq-
uisite for the generic module of the PESaM to be valid.
Especially with medications for rare (and often severe)
diseases, the presence of side effects and inconvenience of
administration may not lead to overall dissatisfaction.
Therefore, rather than serving as a satisfaction measure
alone, the generic module evaluates both experiences and
satisfaction.
A recently published opinion piece by IPF experts
illustrates the potential value of the PESaM questionnaire
[7]. In IPF, there is a paucity of specific well-validated
patient-reported outcome and experience measures, while it
is increasingly acknowledged that understanding what
matters to patients is essential for patient-centred care and
research. PROMs, like the PESaM, focusing on the impact
of therapy on a patient’s well-being and daily life, have the
potential to facilitate communication between patient and
care provider [64], detect unrecognised problems and guide
treatment choice [7, 65, 66]. The disease-specific module
provides detailed insight into the impact of the antifibrotic
agents on specific disease symptoms such as cough and
fatigue, as well as how bothered patients are with experi-
encing side effects. The generic module of the PESaM
questionnaire could be included as secondary or explora-
tory endpoints in trials or registries. Systematic collection
of patient experiences with pirfenidone and nintedanib, for
example, enables better understanding of variable treat-
ment response and identification of subgroups of patients
that might benefit from a certain treatment [2]. What is
more, with new (orphan) drugs continuously being devel-
oped and entering the market, regulatory bodies will
require proof of value for money. In The Netherlands, the
ZiNL has the responsibility of advising the Minister of
Health, Welfare and Sport about what should be included
in the basic health care package. The advisory process of
the ZiNL consists of four phases: scoping, assessment,
appraisal and final advice formalising. In the assessment
phase, all relevant information regarding the four criteria of
necessity, effectiveness, cost effectiveness and feasibility
are collected. An appraisal phase is included if the evi-
dence in the assessment phase was not convincing enough
or if important societal implications are expected. A
committee assigned by the Minister then reassesses the
information from the different package criteria, giving
special consideration to the societal implications. In both
phases, external parties, including patient organisations and
clinicians, are asked for additional evidence or their opin-
ion. Since assessment of value for money for orphan drugs
can be challenged by the rarity of the disease compro-
mising the quality of orphan drug evidence, as well as
unfavourable cost-effectiveness ratios due to their high
costs [67], there is opportunity for the patient perspective,
and thus patient experience measures, to play a more sig-
nificant role when assessing and appraising the value of
orphan drugs. However, to date, the patients’ views and
experiences with medications are often expressed through
personal anecdotes or opinions [25]. Data collected by the
PESaM questionnaire provides much more systematic,
quantitative and robust evidence on how these (orphan)
drugs impact on the lives of patients. The generic module
of the PESaM specifically focuses on the impact of the
medication on physical, emotional and social health, and
allows for comparison with other drugs.
This study has a number of limitations. First, focus
groups and individual interviews (phase II), as well as the
face validity test (phase III), were conducted in a relatively
small population (n = 13, n = 4 and n = 18, respec-
tively). In addition, aHUS patients who participated in the
face-validity testing were the same patients who were
interviewed in phase II. However, aHUS and IPF are rare
diseases and not all patients are eligible for the medica-
tions. Hence, with a set time frame to develop the ques-
tionnaire, a larger pool of eligible patients could not be
identified. Nonetheless, for its next step, psychometric
validation of the questionnaire, the PESaM questionnaire is
currently sent out to IPF patients in The Netherlands who
(start to) use pirfenidone or nintedanib in one of ten par-
ticipating hospitals across the country. Hence, a much
larger study population is expected for the psychometric
validation. Similarly, in order to receive eculizumab, aHUS
patients are required to take part in a national monitoring
study in which patient experiences and satisfaction, as
assessed by the PESaM questionnaire, are secondary out-
come measures. Finally, to promote generalisability of the
generic module, psychometric validation is also conducted
in a third patient group not involved in the development of
the questionnaire. The generic experiences module of the
PESaM is completed (three times, including a test–retest)
by adult patients who have had a kidney or liver transplant
and are using the drug advagraf to prevent rejection. Sec-
ond, patients involved in the development and pretesting of
the questionnaire were all still receiving the therapy. This
could have introduced bias towards the generally more
satisfied patients, generating a risk that an important issue
or domain causing patients to discontinue the medication
was overlooked. Nonetheless, several participants of the
focus groups reported severe side effects, which had forced
them to temporarily discontinue therapy or reduce the daily
dosage. Moreover, the face validity interviews included
respondents who had stopped using pirfenidone and had
switched to nintedanib. They did not report missing any
side effects or other important issues related to their
medication use in the PESaM questionnaire. Third, the
decision to develop an expectations module was made after
conclusion of phase II of the project, and did therefore not
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undergo a rigorous development process. Nevertheless, the
module was well received by respondents in the face
validity test. It is expected that responses on the PESaM
expectations module can assist in the psychometric testing
of the generic module: to what extent are experiences and
satisfaction related to prior expectations? Fourth, the
PESaM questionnaire was originally developed for use in
adolescent and adult populations; however, the youngest
participant in the development and pretesting phase was
24 years of age. Hence, it is unknown whether the PESaM
is suitable for use in an adolescent population. The age
range among participants of the validity phase will most
likely be wider, potentially providing evidence for its use
in this population. Still, the majority of participants in the
validity study are IPF patients who are generally older than
20 years of age [37]. Finally, at this point, we are unable to
define cut-off scores for the PESaM, i.e. a score of x means
that a patient has had a positive experience and is satisfied.
Further research is planned to quantitatively evaluate the
psychometric properties and interpretability of the scores,
as well as to assess the impact of the PESaM on clinical
and reimbursement decision making. Once the psychome-
tric properties are established, the questionnaire will be
translated into English.
6 Conclusions
The PESaM questionnaire was developed to quantitatively
and systematically evaluate patient experiences and satis-
faction with medications. Data collected using the PESaM
questionnaire aim to better promote understanding of the
impact of a therapy on a patient’s daily life. It can poten-
tially serve as a tool to assist shared decision making in
clinical practice, as well as provide more scientific evi-
dence towards the patient’s perspective in reimbursement
decision making.
Acknowledgements MK, AR, MW, KW, NvdK, MS, XvJ and CD
contributed to the study design. RM, NT, JW and MG recruited
patients. MK and AR moderated the focus groups and individual
interviews and conducted the qualitative analyses. MK, AR, MW,
KW, NvdK, MS, XvJ, CD, RM, NT, JW and MG all contributed to
the interpretation of the findings and writing of the manuscript. All
authors reviewed and approved the final manuscript.
Compliance with Ethical Standards
Conflict of interest Merel Kimman, Adrienne Rotteveel, Marlies
Wijsenbeek, Re´my Mostard, Nelleke Tak, Xana van Jaarsveld,
Marjolein Storm, Kioa Wijnsma, Marielle Gelens, Nicole van de Kar,
Jack Wetzels and Carmen Dirksen have no conflicts of interest,
including nonfinancial, that are directly relevant to the content of this
article.
Funding This project was funded by The Federation of Patients and
Consumer Organisations in The Netherlands (NPCF), Lung
Foundation Netherlands, and The Netherlands Organisation for
Health Research and Development (ZonMw). We thank Ms Jeanine
van der Giessen (M.Sc.), health literacy specialist, University Medical
Center Utrecht, for reviewing the questionnaires. We also gratefully
acknowledge the support of Ms. Mirjam van Manen (M.Sc.), Ph.D.
candidate at the Department of Respiratory Medicine of the Erasmus
Medical Center in Rotterdam.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Bensing J. Bridging the gap. The separate worlds of evidence-
based medicine and patient-centered medicine. Patient Educ
Couns. 2000;39(1):17–25.
2. Britten N, Pope C, Halford S, Richeldi L. What if we made
stratified medicine work for patients? Lancet Respir Med.
2016;4(1):8–10.
3. Facey K, Boivin A, Gracia J, Hansen HP, Lo Scalzo A, Mossman
J, et al. Patients’ perspectives in health technology assessment: a
route to robust evidence and fair deliberation. Int J Technol
Assess Health Care. 2010;26(3):334–40.
4. Hailey D, Werko S, Bakri R, Cameron A, Gohlen B, Myles S,
et al. Involvement of consumers in health technology assessment
activities by Inahta agencies. Int J Technol Assess Health Care.
2013;29(1):79–83.
5. Krahn M, Naglie G. The next step in guideline development:
incorporating patient preferences. JAMA. 2008;300(4):436–8.
6. Utens CM, van der Weijden T, Joore MA, Dirksen CD. The use
of research evidence on patient preferences in pharmaceutical
coverage decisions and clinical practice guideline development:
exploratory study into current state of play and potential barriers.
BMC Health Serv Res. 2014;14:540.
7. Wijsenbeek M, van Manen M, Bonella F. New insights on patient-
reported outcome measures in idiopathic pulmonary fibrosis: only
PROMises? Curr Opin Pulm Med. 2016;22(5):434–41.
8. van Overveld LF, Braspenning JC, Hermens RP. Quality indi-
cators of integrated care for patients with head and neck cancer.
Clin Otolaryngol. 2017;42(2):322–9.
9. Hendriks M, Dahlhaus-Booij J, Plass AM. Clients’ perspective on
quality of audiology care: development of the Consumer Quality
Index (CQI) ‘Audiology Care’ for measuring client experiences.
Int J Audiol. 2017;56(1):8–15.
10. Zuidgeest M, Sixma H, Rademakers J. Measuring patients’
experiences with rheumatic care: the consumer quality index
rheumatoid arthritis. Rheumatol Int. 2009;30(2):159–67.
11. Ahmed F, Burt J, Roland M. Measuring patient experience:
concepts and methods. Patient. 2014;7(3):235–41.
12. Rademakers J, Delnoij D, Boer D. Structure, process or outcome:
which contributes most to patients’ overall assessment of
healthcare quality? BMJ Qual Saf. 2011;20(4):326–31.
13. Anhang Price R, Elliott MN, Zaslavsky AM, Hays RD, Lehrman
WG, Rybowski L, et al. Examining the role of patient experience
surveys in measuring health care quality. Med Care Res Rev.
2014;71(5):522–54.
14. Cleary PD. Evolving concepts of patient-centered care and the
assessment of patient care experiences: optimism and opposition.
J Health Polit Policy Law. 2016;41(4):675–96.
M. L. Kimman et al.
15. Claessen SJ, Francke AL, Sixma HJ, de Veer AJ, Deliens L.
Measuring patients’ experiences with palliative care: the Con-
sumer Quality Index Palliative Care. BMJ Support Palliat Care.
2012;2(4):367–72.
16. Shikiar R, Rentz AM. Satisfaction with medication: an overview
of conceptual, methodologic, and regulatory issues. Value Health.
2004;7(2):204–15.
17. Wolf J, Niederhauser V, Marshburn D, LaVela S. Defining
patient experience. Patient Exp J. 2014;1(1):7–19.
18. Strasser S, Aharony L, Greenberger D. The patient satisfaction
process: moving toward a comprehensive model. Med Care Rev.
1993;50(2):219–48.
19. Entwistle V, Firnigl D, Ryan M, Francis J, Kinghorn P. Which
experiences of health care delivery matter to service users and
why? A critical interpretive synthesis and conceptual map.
J Health Serv Res Policy. 2012;17(2):70–8.
20. Utens CM, Joore MA, van der Weijden T, Dirksen CD. Towards
integration of research evidence on patient preferences in coverage
decisions and clinical practice guidelines: a proposal for a taxonomy
of preference-related terms. Value Health. 2014;17(7):A583–4.
21. Laba TL, Essue B, Kimman M, Jan S. Understanding patient
preferences in medication nonadherence: a review of stated
preference data. Patient. 2015;8(5):385–95.
22. Kane RL, Maciejewski M, Finch M. The relationship of patient
satisfaction with care and clinical outcomes. Med Care.
1997;35(7):714–30.
23. Lindhiem O, Bennett CB, Trentacosta CJ, McLear C. Client
preferences affect treatment satisfaction, completion, and clinical
outcome: a meta-analysis. Clin Psychol Rev. 2014;34(6):506–17.
24. Shingler SL, Bennett BM, Cramer JA, Towse A, Twelves C,
Lloyd AJ. Treatment preference, adherence and outcomes in
patients with cancer: literature review and development of a
theoretical model. Curr Med Res Opin. 2014;30(11):2329–41.
25. Dirksen CD. The use of research evidence on patient preferences
in health care decision-making: issues, controversies and moving
forward. Expert Rev Pharmacoecon Outcomes Res.
2014;14(6):785–94.
26. van de Bovenkamp HM, Zuiderent-Jerak T. An empirical study
of patient participation in guideline development: exploring the
potential for articulating patient knowledge in evidence-based
epistemic settings. Health Expect. 2015;18(5):942–55.
27. Boon W, Martins L, Koopmanschap M. Governance of condi-
tional reimbursement practices in The Netherlands. Health Pol-
icy. 2015;119(2):180–5.
28. Thompson AG, Sunol R. Expectations as determinants of patient
satisfaction: concepts, theory and evidence. Int J Qual Health
Care. 1995;7(2):127–41.
29. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK,
et al. An official ATS/ERS/JRS/ALAT statement: idiopathic
pulmonary fibrosis: evidence-based guidelines for diagnosis and
management. Am J Respir Crit Care Med. 2011;183(6):788–824.
30. Ley B, Collard HR, King TE Jr. Clinical course and prediction of
survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care
Med. 2011;183(4):431–40.
31. Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J,
et al. An official ATS/ERS/JRS/ALAT clinical practice guide-
line: treatment of idiopathic pulmonary fibrosis. An update of the
2011 clinical practice guideline. Am J Respir Crit Care Med.
2015;192(2):e3–19.
32. Fukihara J, Kondoh Y. Nintedanib (OFEV) in the treatment of
idiopathic pulmonary fibrosis. Expert Rev Respir Med.
2016;10(12):1247–54.
33. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK,
Costabel U, et al. Efficacy and safety of nintedanib in idiopathic
pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.
34. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA,
Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in
patients with idiopathic pulmonary fibrosis. N Engl J Med.
2014;370(22):2083–92.
35. Trawinska MA, Rupesinghe RD, Hart SP. Patient considerations
and drug selection in the treatment of idiopathic pulmonary
fibrosis. Ther Clin Risk Manag. 2016;12:563–74.
36. Bridges JF, Paly VF, Barker E, Kervitsky D. Identifying the
benefits and risks of emerging treatments for idiopathic pul-
monary fibrosis: a qualitative study. Patient. 2015;8(1):85–92.
37. Nalysnyk L, Cid-Ruzafa J, Rotella P, Esser D. Incidence and
prevalence of idiopathic pulmonary fibrosis: review of the liter-
ature. Eur Respir Rev. 2012;21(126):355–61.
38. Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syn-
drome. Orphanet J Rare Dis. 2011;6:60.
39. Verhave JC, Wetzels JF, van de Kar NC. Novel aspects of
atypical haemolytic uraemic syndrome and the role of eculizu-
mab. Nephrol Dial Transpl. 2014;29(Suppl 4):iv131–41.
40. Baskin E, Gulleroglu K, Kantar A, Bayrakci U, Ozkaya O.
Success of eculizumab in the treatment of atypical hemolytic
uremic syndrome. Pediatr Nephrol. 2015;30(5):783–9.
41. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Fremeaux-Bacchi
V. Use of eculizumab for atypical haemolytic uraemic syndrome
and C3 glomerulopathies. Nat Rev Nephrol. 2012;8(11):643–57.
42. Sav A, King MA, Whitty JA, Kendall E, McMillan SS, Kelly F,
et al. Burden of treatment for chronic illness: a concept analysis
and review of the literature. Health Expect. 2015;18(3):312–24.
43. Brod M, Tesler LE, Christensen TL. Qualitative research and
content validity: developing best practices based on science and
experience. Qual Life Res. 2009;18(9):1263.
44. Willis GB, Artino AR. What do our respondents think we’re
asking? Using cognitive interviewing to improve medical edu-
cation surveys. J Grad Med Educ. 2013;5(3):353–6.
45. Atkinson MJ, Stewart WC, Fain JM, Stewart JA, Dhawan R,
Mozaffari E, et al. A new measure of patient satisfaction with
ocular hypotensive medications: the Treatment Satisfaction Sur-
vey for Intraocular Pressure (TSS-IOP). Health Qual Life Out-
comes. 2003;1:67.
46. Barber BL, Strahlman ER, Laibovitz R, Guess HA, Reines SA.
Validation of a questionnaire for comparing the tolerability of
ophthalmic medications. Ophthalmology. 1997;104(2):334–42.
47. Flood EM, Beusterien KM, Green H, Shikiar R, Baran RW,
Amonkar MM, et al. Psychometric evaluation of the Osteoporosis
Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a
novel measure to assess satisfaction with bisphosphonate treat-
ment in postmenopausal women. Health Qual Life Outcomes.
2006;4:42.
48. Vernon MK, Revicki DA, Awad AG, Dirani R, Panish J, Canuso
CM, et al. Psychometric evaluation of the Medication Satisfac-
tion Questionnaire (MSQ) to assess satisfaction with antipsy-
chotic medication among schizophrenia patients. Schizophr Res.
2010;118(1–3):271–8.
49. Brod M, Christensen T, Kongso JH, Bushnell DM. Examining
and interpreting responsiveness of the Diabetes Medication Sat-
isfaction measure. J Med Econ. 2009;12(4):309–16.
50. Kimel M, Hsieh R, McCormack J, Burch SP, Revicki DA. Val-
idation of the revised Patient Perception of Migraine Question-
naire (PPMQ-R): measuring satisfaction with acute migraine
treatment in clinical trials. Cephalalgia. 2008;28(5):510–23.
51. Campbell JL, Kiebert GM, Partridge MR. Development of the
satisfaction with inhaled asthma treatment questionnaire. Eur
Respir J. 2003;22(1):127–34.
52. Mathias SD, Warren EH, Colwell HH, Sung JC. A new treatment
satisfaction measure for asthmatics: a validation study. Qual Life
Res. 2000;9(7):873–82.
Development of the PESaM Questionnaire
53. Pouchot J, Trudeau E, Hellot SC, Meric G, Waeckel A, Goguel J.
Development and psychometric validation of a new patient sat-
isfaction instrument: the osteoARthritis Treatment Satisfaction
(ARTS) questionnaire. Qual Life Res. 2005;14(5):1387–99.
54. Baro E, Casado A, Garcia-Cases C, Clerch L, Ribas S. Assessing
satisfaction with pain medication in primary care patients:
development and psychometric validation of a new measure. Clin
Ther. 2004;26(7):1124–36.
55. Evans CJ, Trudeau E, Mertzanis P, Marquis P, Pena BM, Wong J,
et al. Development and validation of the Pain Treatment Satis-
faction Scale (PTSS): a patient satisfaction questionnaire for use
in patients with chronic or acute pain. Pain. 2004;112(3):254–66.
56. Coyne K, Joshua-Gotlib S, Kimel M, Thompson C, Lewis A,
Danilewitz M. Validation of the treatment satisfaction question-
naire for Crohn’s disease (TSQ-C). Dig Dis Sci.
2005;50(2):252–8.
57. Margolis MK, Fox KM, Cerulli A, Ariely R, Kahler KH, Coyne
KS. Psychometric validation of the overactive bladder satisfac-
tion with treatment questionnaire (OAB-SAT-q). Neurourol
Urodyn. 2009;28(5):416–22.
58. Abetz L, Coombs JH, Keininger DL, Earle CC, Wade C, Bury-
Maynard D, et al. Development of the cancer therapy satisfaction
questionnaire: item generation and content validity testing. Value
Health. 2005;8(Suppl 1):S41–53.
59. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod
M, et al. Validation of a general measure of treatment satisfac-
tion, the Treatment Satisfaction Questionnaire for Medication
(TSQM), using a national panel study of chronic disease. Health
Qual Life Outcomes. 2004;2:12.
60. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical
construct validity of the treatment satisfaction questionnaire for
medication (TSQM version II) among outpatient pharmacy con-
sumers. Value Health. 2005;8(Suppl 1):S9–24.
61. Ruiz MA, Pardo A, Rejas J, Soto J, Villasante F, Aranguren JL.
Development and validation of the ‘‘Treatment Satisfaction with
Medicines Questionnaire’’ (SATMED-Q). Value Health.
2008;11(5):913–26.
62. de Vet HCW, Terwee CB, Mokkink LB, Knol DL. Measurement
in medicine: a practical guide. Cambridge: Cambridge University
Press; 2011.
63. Kroenke K, Monahan PO, Kean J. Pragmatic characteristics of
patient-reported outcome measures are important for use in
clinical practice. J Clin Epidemiol. 2015;68(9):1085–92.
64. Jacobson TA, Edelman SV, Galipeau N, Shields AL, Mallya UG,
Koren A, et al. Development and content validity of the Statin
Experience Assessment Questionnaire (SEAQ)(c). Patient. [Epub
15 Dec 2016]. doi:10.1007/s40271-016-0211-y.
65. Chen J, Ou L, Hollis SJ. A systematic review of the impact of
routine collection of patient reported outcome measures on
patients, providers and health organisations in an oncologic set-
ting. BMC Health Serv Res. 2013;13:211.
66. Santana MJ, Feeny D. Framework to assess the effects of using
patient-reported outcome measures in chronic care management.
Qual Life Res. 2014;23(5):1505–13.
67. Drummond MF. Challenges in the economic evaluation of orphan
drugs. Eurohealth. 2008;14(2):16–7.
M. L. Kimman et al.
